These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1094 related articles for article (PubMed ID: 1676590)
1. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Hanauer SB; Stathopoulos G Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590 [TBL] [Abstract][Full Text] [Related]
2. Drug therapy of inflammatory bowel disease. Sack DM; Peppercorn MA Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027 [TBL] [Abstract][Full Text] [Related]
3. Comparative tolerability of treatments for inflammatory bowel disease. Stein RB; Hanauer SB Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348 [TBL] [Abstract][Full Text] [Related]
5. Newer pharmacologic agents for the therapy of inflammatory bowel disease. Ruderman WB Med Clin North Am; 1990 Jan; 74(1):133-53. PubMed ID: 2404172 [TBL] [Abstract][Full Text] [Related]
6. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
7. How important is onset of action in ulcerative colitis therapy? Masson S; Nylander D; Mansfield JC Drugs; 2005; 65(15):2069-83. PubMed ID: 16225364 [TBL] [Abstract][Full Text] [Related]
8. A practical guide to the management of distal ulcerative colitis. Ardizzone S; Bianchi Porro G Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342 [TBL] [Abstract][Full Text] [Related]
9. Current status of drug therapy for inflammatory bowel disease. Peppercorn MA Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of aminosalicylates in inflammatory bowel disease. Ishaq S; Green JR BioDrugs; 2001; 15(5):339-49. PubMed ID: 11437696 [TBL] [Abstract][Full Text] [Related]
13. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
14. Optimizing therapy for inflammatory bowel disease. Robinson M Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347 [TBL] [Abstract][Full Text] [Related]
15. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138 [TBL] [Abstract][Full Text] [Related]
16. Review article: maintenance treatment of Crohn's disease. Biancone L; Tosti C; Fina D; Fantini M; De Nigris F; Geremia A; Pallone F Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():31-7. PubMed ID: 12786610 [TBL] [Abstract][Full Text] [Related]
17. Drug therapy for inflammatory bowel disease: Part I. Linn FV; Peppercorn MA Am J Surg; 1992 Jul; 164(1):85-9. PubMed ID: 1626611 [TBL] [Abstract][Full Text] [Related]
18. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Connell W; Miller A Drug Saf; 1999 Oct; 21(4):311-23. PubMed ID: 10514022 [TBL] [Abstract][Full Text] [Related]
19. Advances in drug therapy for inflammatory bowel disease. Peppercorn MA Ann Intern Med; 1990 Jan; 112(1):50-60. PubMed ID: 2152845 [TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy. Hawthorne AB; Hawkey CJ Drugs; 1989 Aug; 38(2):267-88. PubMed ID: 2670519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]